Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

NCT02571036 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.

NCT NCT02571036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02571036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies
Lead sponsor
Deciphera Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2015
Completion date
April 29, 2022
Enrollment
282 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers, advanced systemic mastocytosis, gastrointestinal stromal tumors